Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Completed 16Active not recruiting 6Recruiting 5Terminated 4Unknown 3Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 134Breast Neoplasms 94Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 45Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Carcinoma, Renal Cell 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Multiple Myeloma 18Biliary Tract Neoplasms 18

Interventions

surufatinib 1nimotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Adenoma, Islet Cell × Clear all
NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Changhai Hospital

Phase 2 Not yet recruiting
100 enrolled

Adenoma, Islet Cell

NCT05316480 2022-04-07

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Fudan University

Phase 2 Not yet recruiting
42 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡